Skip to content
TrialScanner

NCT03650894

Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients

Phase 2Active, not recruitingBMYCollaborator

Registry record

Lead sponsor
Providence Health & Services
Conditions
Breast Neoplasm Female; Breast Cancer; Breast Carcinoma; Breast Tumor
Primary completion
Mar 10, 2023Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03650894 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03650894: Nivolumab, Ipilimumab, and... | TrialScanner